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Acetyl-L-carnitine for symptomatic diabetic 
neuropathy
Dear Sir,
Diabetic neuropathy is a progressive disorder that causes func­
tional and structural alterations of peripheral nerves. Accord­
ing to a recent survey in a hospital clinic population in the 
United Kingdom, the overall prevalence of diabetic peripher­
al neuropathy may be as high as 28,5 % [1]. A beneficial effect 
of acetyl-L-carnitine (ALC) on nerve function has been dem­
onstrated in animal models of diabetes [2, 3]; moreover, ALC 
levels are decreased in sciatic nerve from streptozotocin-dia- 
betic rats [4], ALC is an endogenous substance similar in struc­
ture to acetylcholine and is involved in uptake and oxidation of 
long-chain fatty acids in mitochondria [5].
We evaluated the therapeutic effectiveness of ALC in 20 
(14 female/6 male) diabetic subjects (age 58 ± 3 years, 
mean ± SD, diabetes duration 18 ± 6 years) with symptomatic 
peripheral diabetic neuropathy. Diabetic treatment was insu­
lin for 13 patients and oral tablets for the other 7 diabetic sub­
jects. All patients were troubled by symptoms of burning, 
shooting pain or tingling in the legs. After stopping any previ­
ous analgesic or anti-inflammatory drug, they entered a sin­
gle-blind, randomized, placebo-controlled, cross-over study in 
which ALC (an intramuscular vial, 500 mg, twice a day), or 
placebo treatments lasted 15 days and were separated by a 2- 
week wash-out period. The patients who received ALC on the 
first occasion took the placebo later and vice versa. The sever­
ity of symptoms was assessed by a visual analogue scale grad­
ed from 0 to 10 (0 = no symptoms, 10 = very severe) (Table 1). 
A significant (p < 0.01) amelioration of symptoms occurred 
when patients took ALC as compared to placebo treatment. 
Vibration perception threshold (VPT), measured at the great 
toe and the external malleolus of the dominant leg, was above 
the upper limit of normal adjusted for age and did not show 
any significant change after ALC or placebo.
There are several ways by which ALC may exert beneficial 
effects on nerve function in diabetic patients. ALC has been 
shown to acutely increase the plasma concentration of the en­
dogenous opioid peptide beta-endorphin in healthy volun­
teers (analgesic effect) [6]; ALC increases the number of 
nerve growth factor receptors on the brain and prevents sub­
stance P loss in the sciatic nerve and spinal cord of diabetic an­
imals (n euro tropic effect) [7]; ALC influences mitochondrial 
protein synthesis and transport and non-esterified fatty acid 
oxidation, thereby increasing the oxidative metabolism of neu­
rons (metabolic effect) [5]; lastly, ALC enhances the activity of 
antioxidant factors, such as reduced glutathione, and protects
Table 1, The effect of acetyl-L-carnitine (ALC) in symptomatic 
peripheral diabetic neuropathy
Pain scale VPT (volts)
Great toe External malleolus
Basal 7.4 ±1.1 19 ±2.4 23 ±3
Placebo 7.4 ±1.3 19 ±2.2 23.5 ±2.8
ALC 3.6 ± 1.7U 18 ± 2.1 23 ±1.9
the cells against lipid peroxidation (free radical scavenging ef­
fect) [8]. Recent evidence suggests that oxidative injury may 
be the ultimate factor of aggression to the diabetic nerve [9]. 
Long-term controlled studies will tell us whether ALC has a 
role in the treatment of symptomatic diabetic neuropathy.
A. Quatraro, P. Roca, C. Donzella, R.Acampora, R. Marfella,
D. Giugliano
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malleolus both at the dominant leg, a p < 0.01 vs placebo
Antihypertensives retarding progression 
of diabetic nephropathy
Dear Sir,
With interest I read the study of Elving et al. [1] comparing the 
effects of atenolol and captopril in retarding progression of di­
abetic nephropathy.
The authors fail to distinguish between results which are 
identical and those which are not statistically significantly dif­
ferent. For example, baseline values for blood pressure in the 
captopril-treated group and the atenolol-treated group were 
described as “identical” despite a 5 mm Hg difference in mean 
arterial pressure (MAP). In a meta-analysis of observational 
blood pressure studies involving 420,000 patients, a 5 mmHg
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difference in diastolic pressure was associated with 34% less 
stroke and 21 % less coronary heart disease [2]. Similarly, al­
though MAP in the two groups fell to the same level, the dif­
ference in the fall (—10 mmHg MAP in the captopril group vs 
-4  mm Hg MAP in the atenolol group) may well be biological­
ly significant [3] even if it is not statistically significant.
Albuminuria was described as “identical” at baseline (1549 
vs 933 mg/24 h in the two groups), and as being reduced to the 
“same extent” (1549 to 851 (-59%) for captopril and 933 to 
676 (-18%) for atenolol. The differences may not have been 
statistically significant but can hardly be described as “identi­
cal”. Indeed, when the authors eliminated several spurious 
outliers (a risky practice), there was a statistically significant 
difference in MAP and albuminuria in favour of the capto- 
pril-treated group (for MAP -10.6 vs -5.2, p < 0.05 and for al­
buminuria -60 % vs -20 % ,p < 0.01).
Was a power calculation performed before the study and if 
so, what difference in blood pressure was taken to be biologi­
cally significant? Given that very small differences in blood 
pressure have been found to be biologically significant [2, 3], 
the risk of a type II error in this study must be high. To con­
clude that ACE-inhibitors and beta-blockers are equally effec­
tive in retarding progression of diabetic nephropathy on the 
basis of these data is an overstatement.
Yours sincerely,
Dr. K.J.Hardy
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100.8 ±8.5 mmHg in the captopril- and atenolol-treated pa­
tients, respectively. To detect a 50 % difference in the effects 
of captopril and atenolol on the decline in glomerular filtra­
tion rate with a power of 80%, 16 patients in each treatment 
group would have been needed. The actual number of pa­
tients (29, instead of 32) is within an acceptable margin. As 
we mentioned in our paper, from our data it can be calculated 
that the chance that captopril is 50 % better than atenolol is
4.8 %. It is therefore unlikely that we have missed such a differ­
ence. We agree that smaller differences (in either direction) 
might go undetected in our study. To prove this, studies with 
more patients or studies of longer duration will be needed.
L. D. Elving, J. F. M. Wetzels, H. J. J. van Lier,
E. de Nobel, J. H. M. Berden
Use of terminology related to fetal insulin 
secretion
Dear Sir,
I enjoyed reading Hughes’ paper [1] which reports some useful 
new information relating to insulin secretion by fetal as com­
pared to neonatal rat pancreatic islets. My purpose in writing 
is to suggest a change in perception and terminology in this 
field. Fetal insulin secretion is variously described as “imma­
ture”, “poor”, “abnormal”, “failed” (to release) and to have 
“impaired coupling”. Similar terms are used in relation to me­
tabolism in fetal islets.
There is abundant evidence that insulin production and ac­
tion in the fetus is of critical importance for normal fetal 
growth and development [2], Thus, fetal insulin secretion 
must be judged to be entirely normal, mature, appropriate 
and property coupled for the roles it fulfils in fetal physiology. 
My purpose in making what might otherwise be thought to be 
a rather pedantic point is to suggest that research on fetal insu­
lin secretion is in danger of focusing on how “odd” it is rather 
than on the more interesting questions of how and why it is es­
tablished with such a different regulation from that in the 
adult.
Yours faithfully,
C.N. Hales
Response from the authors
Dear Sir,
We thank Dr. Hardy for his comment. We did not perform a 
power calculation based on blood pressure differences. Our 
study was designed to examine a possible beneficial effect of 
ACE-inhibitors, compared to beta-blockers, on the progres­
sion of diabetic nephropathy (measured as decline in glomeru­
lar filtration rate) independent of blood pressure control. In 
that regard it was important to attain similar levels of blood 
pressure during the study in both treatment groups. We cer­
tainly feel that we have succeeded in this respect. The 
mean ± SD of all blood pressure measurements during the 2- 
year follow-up (17 visits in each patient) was 100.9 ± 6.0 and
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